Jessica Ricciuto, MD
Endocrinology, Diabetes & Metabolism · Danvers, MANPI 1316208622
Payments from drug & device makers
Across 67 payments — averaging $17.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$298
- Novo Nordisk$150
- Sanofi-aventis U.S. LLC$127
- Boehringer Ingelheim$115
- Radius Health, Inc.$111
- Lilly USA, LLC$65
- plus $337 from 14 others
What the payments were for
- Food & beverage$1,16997%
- Education$343%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 11 | $298 |
| Novo Nordisk | 13 | $150 |
| Sanofi-aventis U.S. LLC | 8 | $127 |
| Boehringer Ingelheim | 6 | $115 |
| Radius Health, Inc. | 4 | $111 |
| Lilly USA, LLC | 4 | $65 |
| Merck | 3 | $41 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $38 |
| AbbVie | 2 | $37 |
| Amarin Pharma, Inc. | 2 | $34 |
| Amgen | 2 | $30 |
| Ascensia Diabetes Care US Inc. | 2 | $28 |
| BD | 1 | $22 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
| Medtronic | 1 | $18 |
| Shire North American Group Inc | 1 | $17 |
| Mannkind Corporation | 1 | $16 |
| Endo Pharmaceuticals Inc. | 1 | $14 |
| Antares Pharma, Inc. | 1 | $13 |
| Amneal Pharmaceuticals LLC | 1 | $12 |
How this compares
$1,203 in reported general payments places this provider in the 50th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
See all endocrinology, diabetes & metabolism providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 322 | $661,737 |
| MounjaroTirzepatide | 213 | $404,108 |
| TrulicityDulaglutide | 219 | $397,985 |
| JardianceEmpagliflozin | 131 | $204,040 |
| FarxigaDapagliflozin Propanediol | 45 | $61,633 |
| Tresiba Flextouch U-200Insulin Degludec | 48 | $58,047 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 31 | $54,552 |
| TymlosAbaloparatide | 18 | $47,984 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 67 | $43,870 |
| Tresiba Flextouch U-100Insulin Degludec | 71 | $41,009 |
| JanuviaSitagliptin Phosphate | 26 | $39,417 |
| Humalog Kwikpen U-200Insulin Lispro | 12 | $36,725 |
| RybelsusSemaglutide | 17 | $30,715 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 24 | $30,714 |
| Teriparatide | 11 | $25,541 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $65 | $802,093432 claims |
| Novo NordiskOzempic, Rybelsus | $150 | $692,452339 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $115 | $258,592162 claims |
| AstraZenecaFarxiga | $298 | $61,63345 claims |
| Radius Health, Inc.Tymlos | $111 | $47,98418 claims |
| MerckJanuvia | $41 | $39,41726 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $12 | $7,657527 claims |
| AbbVieSynthroid | $37 | $7,306115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
Other endocrinology, diabetes & metabolism in Danvers
- David NathanBoston$9M
- Vanita ArodaBoston$4.2M
- George KingBoston$3.7M
- Karen MillerBoston$2.9M
- Steven GrinspoonBoston$2.7M
- Jason GagliaBoston$2.5M
- Tamer YacoubFall River$1.4M
- Elaine YuBoston$1.3M
- Osama HamdyBoston$1.1M
- Steven RussellBoston$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.